Warning Letter - MM&M - Medical Marketing and Media

Warning Letter

DDMAC vows pushback on risk disclosures

The FDA has stepped up efforts to combat what it sees as the No. 1 pharmaceutical marketing compliance problem, said Division of Drug Marketing, Advertising and Communication chief Thomas Abrams: ads that omit or downplay risk information.